Perfusion Abnormalities in Hypertrophic Cardiomyopathy

University of Virginia

Status: Not yet enrolling

Conditions: Hypertrophic Cardiomyopathy (HCM)

Treatments: Diagnostic Test: myocardial contrast echo

Study type: Observational

Funder types: Other

Identifiers

NCT06599229

301910

Details and patient eligibility

About

The purpose of this study is to investigate whether myocardial microvascular perfusion in patients with hypertrophic cardiomyopathy improved after initiation of cardiac myosin inhibitor therapy.

Enrollment: 30 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of hypertrophic cardiomyopathy
• Subject being initiated on clinically-indicated cardiac myosin inhibitor therapy

Exclusion criteria

• Pregnancy
• Lactation
• Allergy to ultrasound enhancing agent (lipid-stabilized) or regadenoson
• Serious AE to regadenoson
• Hypotension
• Serious bradycardia not addressed by pacemaker
• Moderate or greater reactive airways disease

Trial design

30 participants in 1 patient group

Patients with HCM initiated on cardiac myosin inhibitor therapy

Description:

Patients with HCM who are being initiated on cardiac myosin inhibitor therapy for clinically indicated reasons.

Treatment:

Diagnostic Test: myocardial contrast echo